Logo

Biogen and Samsung Bioepis Launch Byooviz (biosimilar, ranibizumab) for the Treatment of Retinal Vascular Disorders in the US

Share this
Biogen and Samsung Bioepis Launch Byooviz (biosimilar, ranibizumab) for the Treatment of Retinal Vascular Disorders in the US

Biogen and Samsung Bioepis Launch Byooviz (biosimilar, ranibizumab) for the Treatment of Retinal Vascular Disorders in the US

Shots:

  • The company launches Byooviz, a biosimilar referencing ranibizumab as an affordable treatment option for retinal vascular disorders in the US. The therapy is expected to be available in July 2022 through major distributors across the US with a list price of $1,130 per single-use vial to administer 0.5g via IV inj.
  • This list price is ~40% lower than the list price of Lucentis. Ranibizumab is used to treat wet AMD, DME, PDR, macular edema secondary to retinal vein occlusion, or CNV
  • Byooviz marks the first US FDA-approved ophthalmology biosimilar while Byooviz was also approved in Canada, the EU & UK. Samsung is responsible for the development, regulatory registration & manufacture of the products while Biogen is responsible for commercialization

Ref: Biogen | Image: Biogen

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions